^
Сычев Д.А., Михеева Е.С., Кропачева Е.С. и др. Влияние полиморфизма гена CYP2C9 на фармакокинетику и фармакодинамику Варфарина у больных с постоянной формой фибрилляции предсердий. Клиническая медицина 2007; 1: 57-60
Andrea G., Ambrosio R., Di Perna P. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105: 645-649.
Ишемическая болезнь сердца
Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German Aspirin Trial: A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980;suppl V;V63-V72
Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarctions. N Engl J Med 1990;323:147-152
Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, Van der Pol JMJ, Van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT Study. Circulation 1993;87:1524-1530
AnticoaguAnticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503
The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708
Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER Study): a multicentre unblinded randomised clinical trial. Brit Med J 1996;313:1429-1431
Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end-points analysis from the ATACS trial. Circulation 1994;89:81-88
Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-396
Ezekowitz M. The CHAMP study. Presented 72th Scientific Sessions American Heart Association, Atlanta, November 1999
Verheugt FWA. The APRICOT-2 trial. Presented 22th European Congress of Cardiology. Amsterdam, August 2000
Verheugt FWA. The ASPECT-2 trial. Presented 22th European Congress of Cardiology. Amsterdam, August 2000
Medical Research Council Randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk: the Medical Research Council’s General Practice Research Framework Thrombosis Prevention Trial. Lancet1998; 351,233-241
^
Pumphry, CW, Fuster, V, Cheseboro, HJ Systemic thromboembolism in valvular heart disease and prosthetic heart valves. Mod Concepts Cardiovasc Dis 1982, 51,131-136
Fitzgerald, GA Dipyridamole. N Engl J Med 1987, 316,1247-1257
Eckman, MH, Levine, HJ, Salem, DN, et al Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1998, 114(suppl),699S-714S
Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1995; 108: 360s-370s.
Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves [published erratum appears in Chest 1996; 109: 592]. Chest 1995; 108: 371s-379s
Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology. Guidelines for prevention of thromboembolic events in valvular heart disease. J Heart Valve Dis 1993; 2: 398-410
Acar, J, Iung, B, Boissel, JP, et al AREVA: Multicenter randomized comparison of low-dose versus standard dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996,94,2107-2112
Marks, AR, Choong, CY, Sanfilippo, AJ, et al Identification of high-risk and low-risk subgroups of patients with mitral valve prolapse. N Engl J Med,1989 , 320,1031-1036
^
Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis. BMJ 1992; 305: 1460-5.
Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8
Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108: 352s-359s.
Green CJ, Hadorn DC, Bassett K, Kazanjian A. Anticoagulation in chronic nonvalvular atrial fibrillation: A critical appraisal and meta-analysis. Can J Cardiol 1997; 13: 811-5.
^
Levine M, Gent M, Hirsch J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
Koopman MNW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin. N Engl J Med 1996;334:682-687.
The Columbia Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662.
Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin: an economic perspective. Arch Intern Med 1997;157:289-294.
Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669.
Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-236.
White RH, MuCurdy SA, von Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. Ann Intern Med 1989;111:730-737.
Ansell JE, Buttaro ML, Thomas OV, et al. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacotherapy 1997;31:604-615.
Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999;271:145-150.
Ansell JE, Patel N, Ostrovsky D, et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155:2185-2189.
Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months or oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665.
Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-611.
Kearon C, Gent M, Hirst J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.
Simioni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an ARG 506->Gin mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:339-403.
De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-806.
Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1996;157:2174-2177.
Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.
Wahl MJ: Dental surgery in anticoagulated patients. Arch Intern Med; 1998; 158:1610-1616.
Blinder D, Manor Y, Martinowitz U et al: Dental extractions in patients maintained on continued oral anticoagulant: Comparison of local hemostatic modalities. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999; 88:137-140.
|
